Cognitive impairment in chronic ketamine abusers
Related Experiment Video
Updated: Dec 12, 2025

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
Published on: August 18, 2020
Chenxi Zhang1, Yan Xu1, Bin Zhang1
1Department of Psychiatry, Nanfang Hospital, Southern Medical University, Guangzhou, China; Guangdong-Hong Kong-Macao Greater Bay Area Center for Brain Science and Brain-Inspired Intelligence, Guangzhou, China.
Background:
The treatment of ketamine users is substantially challenged by high dropout rates, raising questions regarding contributing factors. A number of studies have highlighted the potential of greater focus on the clinical significance of cognitive impairments in ketamine users. The present study hypothesized that cognitive deficits would play a role in greater risk for treatment dropout in chronic ketamine users.
Methods:
Our study examined cognitive performance in the form of working memory, verbal memory, visual memory and executive function among chronic ketamine users who completed three-month treatment in residential detoxification centres (N = 165), those who dropped out prematurely (N = 121) and drug-free healthy controls (N = 111). The data collection was completed in Hong Kong among the East Asia population.
Results:
Compared to healthy controls, cognitive impairments were found in ketamine users, including in verbal/visual memory and executive function. Executive dysfunction was significantly associated with dropout in ketamine users within three months.
Conclusion:
Our findings suggest that executive dysfunction may have clinical benefits in ketamine users admitted to residential treatment programmes.
More Related Videos
05:12Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder
Published on: June 23, 2023
07:04A High-performance Liquid Chromatography Measurement of Kynurenine and Kynurenic Acid: Relating Biochemistry to Cognition and Sleep in Rats
Published on: August 19, 2018
Related Concept Videos
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
CNS Depressants: Alcohol and Nicotine
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment